X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA FRESENIUS KABI ONCO. SHASUN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 123.9 22.1 559.9% View Chart
P/BV x 8.5 3.1 274.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
SHASUN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs94176 53.5%   
Low Rs4679 58.1%   
Sales per share (Unadj.) Rs214.237.7 568.3%  
Earnings per share (Unadj.) Rs5.35.1 104.8%  
Cash flow per share (Unadj.) Rs15.86.7 235.3%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.342.5 125.4%  
Shares outstanding (eoy) m56.62158.23 35.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.7%   
Avg P/E ratio x13.125.0 52.4%  
P/CF ratio (eoy) x4.418.9 23.3%  
Price / Book Value ratio x1.33.0 43.8%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,95820,135 19.7%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,164703 307.7%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m12,1275,963 203.4%  
Other income Rs m22918 1,274.2%   
Total revenues Rs m12,3565,981 206.6%   
Gross profit Rs m1,0091,430 70.6%  
Depreciation Rs m594258 230.2%   
Interest Rs m415-26 -1,596.5%   
Profit before tax Rs m2301,216 18.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m-73342 -21.3%   
Profit after tax Rs m302806 37.5%  
Gross profit margin %8.324.0 34.7%  
Effective tax rate %-31.728.1 -112.5%   
Net profit margin %2.513.5 18.4%  
BALANCE SHEET DATA
Current assets Rs m6,8845,102 134.9%   
Current liabilities Rs m8,4562,385 354.5%   
Net working cap to sales %-13.045.6 -28.5%  
Current ratio x0.82.1 38.1%  
Inventory Days Days62150 41.1%  
Debtors Days Days108113 94.9%  
Net fixed assets Rs m4,9705,148 96.5%   
Share capital Rs m113158 71.6%   
"Free" reserves Rs m2,8756,556 43.9%   
Net worth Rs m3,0206,732 44.9%   
Long term debt Rs m1,817952 190.9%   
Total assets Rs m13,34710,388 128.5%  
Interest coverage x1.6-45.8 -3.4%   
Debt to equity ratio x0.60.1 425.4%  
Sales to assets ratio x0.90.6 158.3%   
Return on assets %5.47.5 71.6%  
Return on equity %10.012.0 83.6%  
Return on capital %13.314.6 91.2%  
Exports to sales %46.474.5 62.2%   
Imports to sales %14.224.8 57.5%   
Exports (fob) Rs m5,6224,441 126.6%   
Imports (cif) Rs m1,7281,477 116.9%   
Fx inflow Rs m5,8435,298 110.3%   
Fx outflow Rs m2,1731,772 122.6%   
Net fx Rs m3,6693,525 104.1%   
CASH FLOW
From Operations Rs m3981,274 31.2%  
From Investments Rs m-1,635-1,204 135.8%  
From Financial Activity Rs m1,309-196 -667.3%  
Net Cashflow Rs m71-126 -56.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 3.6 0.3 1,200.0%  
FIIs % 17.6 9.6 183.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 9.1 435.2%  
Shareholders   20,750 42,599 48.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS